|
1
|
American College of Obstetricians and
Gynecologists. ACOG Practice Bulletin No. 87 November 2007: Use of
psychiatric medications during pregnancy and lactation. Obstet
Gynecol. 110:1179–1198. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Osborne S, Biaggi A, Chua TE, Du Preez A,
Hazelgrove K, Nikkheslat N, Previti G, Zunszain PA, Conroy S and
Pariante CM: Antenatal depression programs cortisol stress
reactivity in offspring through increased maternal inflammation and
cortisol in pregnancy: The Psychiatry Research and Motherhood -
Depression (PRAM-D) Study. Psychoneuroendocrinology. 98:211–221.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Trifu S, Vladuti A and Popescu A:
Neuroendocrine aspects of pregnancy and postpartum depression. Acta
Endocrinol (Bucur). 15:410–415. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Grote NK, Bridge JA, Gavin AR, Melville
JL, Iyengar S and Katon WJ: A meta-analysis of depression during
pregnancy and the risk of preterm birth, low birth weight, and
intrauterine growth restriction. Arch Gen Psychiatry. 67:1012–1024.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Azar R and Mercer D: Mild depressive
symptoms are associated with elevated C-reactive protein and
proinflammatory cytokine levels during early to midgestation: A
prospective pilot study. J Womens Health (Larchmt). 22:385–389.
2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Davis EP and Sandman CA: The timing of
prenatal exposure to maternal cortisol and psychosocial stress is
associated with human infant cognitive development. Child Dev.
81:131–148. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Braithwaite EC, Murphy SE and Ramchandani
PG: Effects of prenatal depressive symptoms on maternal and infant
cortisol reactivity. Arch Women Ment Health. 19:581–590.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Molenaar NM, Bais B, Lambregtse-van den
Berg MP, Mulder CL, Howell EA, Fox NS, Rommel AS, Bergink V and
Kamperman AM: The international prevalence of antidepressant use
before, during, and after pregnancy: A systematic review and
meta-analysis of timing, type of prescriptions and geographical
variability. J Affect Disord. 264:82–89. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Simoncelli M, Martin BZ and Bérard A:
Antidepressant use during pregnancy: A critical systematic review
of the literature. Curr Drug Saf. 5:153–170. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Trifu S: Neuroendocrine insights into
burnout syndrome. Acta Endocrinol (Bucur). 15:404–405.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Clabault H, Flipo D, Guibourdenche J,
Fournier T, Sanderson JT and Vaillancourt C: Effects of selective
serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts
syncytialization. Toxicol Appl Pharmacol. 349:8–20. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jimenez-Solem E, Andersen JT, Petersen M,
Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C and
Poulsen HE: Exposure to selective serotonin reuptake inhibitors and
the risk of congenital malformations: A nationwide cohort study.
BMJ Open. 2(e001148)2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Grigoriadis S, VonderPorten EH,
Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M,
Mousmanis P, Cheung A, et al: Antidepressant exposure during
pregnancy and congenital malformations: Is there an association? A
systematic review and meta-analysis of the best evidence. J Clin
Psychiatry. 74:e293–e308. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jordan S, Morris JK, Davies GI, Tucker D,
Thayer DS, Luteijn JM, Morgan M, Garne E, Hansen AV, Klungsøyr K,
et al: Selective serotonin reuptake inhibitor (SSRI)
antidepressants in pregnancy and congenital anomalies: Analysis of
linked databases in Wales, Norway and Funen, Denmark. PLoS One.
11(e0165122)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wurst KE, Poole C, Ephross SA and Olshan
AF: First trimester paroxetine use and the prevalence of
congenital, specifically cardiac, defects: A meta-analysis of
epidemiological studies. Birth Defects Res A Clin Mol Teratol.
88:159–170. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Malm H, Artama M, Gissler M and Ritvanen
A: Selective serotonin reuptake inhibitors and risk for major
congenital anomalies. Obstet Gynecol. 118:111–120. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Källén BAJ and Olausson PO: Maternal use
of selective serotonin re-uptake inhibitors in early pregnancy and
infant congenital malformations. Birth Defects Res A Clin Mol
Teratol. 79:301–308. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pop A, Lupu DI, Cherfan J, Kiss B and
Loghin F: Estrogenic/anti-estrogenic activity of selected selective
serotonin reuptake inhibitors. Clujul Med. 88:381–385.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nikfar S, Rahimi R, Hendoiee N and
Abdollahi M: Increasing the risk of spontaneous abortion and major
malformations in newborns following use of serotonin reuptake
inhibitors during pregnancy: A systematic review and updated
meta-analysis. Daru. 20(75)2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Trifu S, Mihailescu R, Stegarescu S and
Ion I: Evolutional perspective over some key-aspects in psychiatry.
In: Theoretical and Applied in Psychology (SICAP23): Psychology and
Ongoing Development. Zamosteanu A (ed.) Medimond s.r.l., Bologna,
pp179-182, 2015.
|
|
21
|
Eke AC, Saccone G and Berghella V:
Selective serotonin reuptake inhibitor (SSRI) use during pregnancy
and risk of preterm birth: A systematic review and meta-analysis.
BJOG. 123:1900–1907. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Levinson-Castiel R, Merlob P, Linder N,
Sirota L and Klinger G: Neonatal abstinence syndrome after in utero
exposure to selective serotonin reuptake inhibitors in term
infants. Arch Pediatr Adolesc Med. 160:173–176. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Man KK, Tong HH, Wong LY, Chan EW,
Simonoff E and Wong IC: Exposure to selective serotonin reuptake
inhibitors during pregnancy and risk of autism spectrum disorder in
children: A systematic review and meta-analysis of observational
studies. Neurosci Biobehav Rev. 49:82–89. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Morales DR, Slattery J, Evans S and Kurz
X: Antidepressant use during pregnancy and risk of autism spectrum
disorder and attention deficit hyperactivity disorder: Systematic
review of observational studies and methodological considerations.
BMC Med. 16(6)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pinheiro E, Bogen DL, Hoxha D, Ciolino JD
and Wisner KL: Sertraline and breastfeeding: Review and
meta-analysis. Arch Women Ment Health. 18:139–146. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Paulzen M, Goecke TW, Stickeler E, Gründer
G and Schoretsanitis G: Sertraline in pregnancy - Therapeutic drug
monitoring in maternal blood, amniotic fluid and cord blood. J
Affect Disord. 212:1–6. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sivojelezova A, Shuhaiber S, Sarkissian L,
Einarson A and Koren G: Citalopram use in pregnancy: Prospective
comparative evaluation of pregnancy and fetal outcome. Am J Obstet
Gynecol. 193:2004–2009. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Grossmann CK, Weitzner B, Pistelli A, Many
A, Lessing J and Koren G: Escitalopram use in pregnancy: An
observational cohort study. Am J Obstet Gynecol. 206(S58)2012.
|
|
29
|
Pereira JD, Caricati-Neto A, Jurkiewicz A
and Jurkiewicz NH: Decreased noradrenergic and serotonergic
reactivity of vas deferens of newborn rats from mothers treated
with the serotonin reuptake inhibitor fluoxetine during pregnancy
and breast-feeding. Life Sci. 81:1501–1508. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Smit-Rigter LA, Noorlander CW, von Oerthel
L, Chameau P, Smidt MP and van Hooft JA: Prenatal fluoxetine
exposure induces life-long serotonin 5-HT3
receptor-dependent cortical abnormalities and anxiety-like
behaviour. Neuropharmacology. 62:865–870. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Glazova NY, Merchieva SA, Volodina MA,
Sebentsova EA, Manchenko DM, Kudrun VS and Levitskaya NG: Effects
of neonatal fluvoxamine administration on the physical development
and activity of the serotoninergic system in white rats. Acta
Naturae. 6:98–105. 2014.PubMed/NCBI
|
|
32
|
Bar-Oz B, Einarson T, Einarson A, Boskovic
R, O'Brien L, Malm H, Bérard A and Koren G: Paroxetine and
congenital malformations: meta-analysis and consideration of
potential confounding factors. Clin Ther. 29:918–926.
2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Paulus WE: Risk of congenital
malformations after maternal treatment with venlafaxine in early
pregnancy. Reprod Toxicol. 37(87)2013.
|
|
34
|
Dandjinou M, Sheehy O and Bérard A:
Antidepressant use during pregnancy and the risk of gestational
diabetes mellitus: A nested case-control study. BMJ Open.
9(e025908)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Holland J and Brown R: Neonatal
venlafaxine discontinuation syndrome: A mini-review. Eur J Paediatr
Neurol. 21:264–268. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Huybrechts KF, Bateman BT, Pawar A,
Bessette LG, Mogun H, Levin R, Li H, Motsko S, Scantamburlo
Fernandes MF, Upadhyaya HP, et al: Maternal and fetal outcomes
following exposure to duloxetine in pregnancy: Cohort study. BMJ.
368(237)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gentile S: Tricyclic antidepressants in
pregnancy and puerperium. Expert Opin Drug Saf. 13:207–225.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
National Collaborating Centre for Mental
Health (UK): Antenatal and Postnatal Mental Health: The NICE
Guideline on Clinical Management and Service Guidance. British
Psychological Society, Leicester, 2007. https://pubmed.ncbi.nlm.nih.gov/21678630/.
|
|
39
|
Armstrong C: ACOG Guidelines on
psychiatric medication use during pregnancy and lactation. Am Fam
Physician. 78:772–778. 2008.
|
|
40
|
Chun-Fai-Chan B, Koren G, Fayez I, Kalra
S, Voyer-Lavigne S, Boshier A, Shakir S and Einarson A: Pregnancy
outcome of women exposed to bupropion during pregnancy: A
prospective comparative study. Am J Obstet Gynecol. 192:932–936.
2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Cole JA, Modell JG, Haight BR, Cosmatos
IS, Stoler JM and Walker AM: Bupropion in pregnancy and the
prevalence of congenital malformations. Pharmacoepidemiol Drug Saf.
16:474–484. 2007.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Einarson A, Bonari L, Voyer-Lavigne S,
Addis A, Matsui D, Johnson Y and Koren G: A multicentre prospective
controlled study to determine the safety of trazodone and
nefazodone use during pregnancy. Can J Psychiatry. 48:106–110.
2003.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Djulus J, Koren G, Einarson TR, Wilton L,
Shakir S, Diav-Citrin O, Kennedy D, Voyer Lavigne S, De Santis M
and Einarson A: Exposure to mirtazapine during pregnancy: A
prospective, comparative study of birth outcomes. J Clin
Psychiatry. 67:1280–1284. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Trifu S, Delcuescu C and Boer CM:
Psychosomatics and psychical tension (clinical research). Procedia
Soc Behav Sci. 33:128–132. 2012.
|
|
45
|
Khan SJ, Fersh ME, Ernst C, Klipstein K,
Albertini ES and Lusskin SI: Bipolar disorder in pregnancy and
postpartum: Principles of management. Curr Psychiatry Rep.
18(13)2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wesseloo R, Kamperman AM, Munk-Olsen T,
Pop VJ, Kushner SA and Bergink V: Risk of postpartum relapse in
bipolar disorder and postpartum psychosis: A systematic review and
meta-analysis. Am J Psychiatry. 173:117–127. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Gentile S: Lithium in pregnancy: The need
to treat, the duty to ensure safety. Expert Opin Drug Saf.
11:425–437. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Deligiannidis KM, Byatt N and Freeman MP:
Pharmacotherapy for mood disorders in pregnancy: A review of
pharmacokinetic changes and clinical recommendations for
therapeutic drug monitoring. J Clin Psychopharmacol. 34:244–255.
2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Forsberg L, Berglund G, Naver L, Ljungdahl
M, Adler M and Wide K: Bipolar disorder and
pregnancy-neurodevelopmental outcome of children exposed to
maternal illness with or without lithium during pregnancy. Arch Dis
Child. 97 (Suppl 2):A184–A185. 2012.
|
|
50
|
van der Lugt NM, van de Maat JS, van Kamp
IL, Knoppert-van der Klein EA, Hovens JG and Walther FJ: Fetal,
neonatal and developmental outcomes of lithium-exposed pregnancies.
Early Hum Dev. 88:375–378. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cohen LS, Friedman JM, Jefferson JW,
Johnson EM and Weiner ML: A reevaluation of risk of in utero
exposure to lithium. JAMA. 271:146–150. 1994.PubMed/NCBI
|
|
52
|
Trifu S: Dissociative identity disorder
Psychotic functioning and impairment of growing-up processes. J
Educ Sci Psychol. 9:102–108. 2019.
|
|
53
|
Grover S and Avasthi A: Mood stabilizers
in pregnancy and lactation. Indian J Psychiatry. 57 (Suppl
2):S308–S323. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Horton S, Tuerk A, Cook D, Cook J and
Dhurjati P: Maximum recommended dosage of lithium for pregnant
women based on a PBPK model for lithium absorption. Adv Bioinforma.
2012(352729)2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Veroniki AA, Rios P, Cogo E, Straus SE,
Finkelstein Y, Kealey R, Reynen E, Soobiah C, Thavorn K, Hutton B,
et al: Comparative safety of antiepileptic drugs for neurological
development in children exposed during pregnancy and breast
feeding: A systematic review and network meta-analysis. BMJ Open.
7(e017248)2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Womersley K: Prescription of sodium
valproate as a mood stabiliser in pregnancy. Psychiatr Danub. 29
(Suppl 3):679–684. 2017.PubMed/NCBI
|
|
57
|
Haskey C and Galbally M: Mood stabilizers
in pregnancy and child developmental outcomes: A systematic review.
Aust N Z J Psychiatry. 51:1087–1097. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Deshmukh U, Adams J, Macklin EA, Dhillon
R, McCarthy KD, Dworetzky B, Klein A and Holmes LB: Behavioral
outcomes in children exposed prenatally to lamotrigine, valproate,
or carbamazepine. Neurotoxicol Teratol. 54:5–14. 2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
McVearry KM, Gaillard WD, VanMeter J and
Meador KJ: A prospective study of cognitive fluency and originality
in children exposed in utero to carbamazepine, lamotrigine, or
valproate monotherapy. Epilepsy Behav. 16:609–616. 2009.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Gentile S: Risks of neurobehavioral
teratogenicity associated with prenatal exposure to valproate
monotherapy: A systematic review with regulatory repercussions. CNS
Spectr. 19:305–315. 2014.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Koch S, Lösche G, Jager-Romän E, Jakob S,
Rating D, Deichl A and Helge H: Major and minor birth malformations
and antiepileptic drugs. Neurology. 42 (Suppl 5):83–88.
1992.PubMed/NCBI
|
|
62
|
Kong L, Zhou T, Wang B, Gao Z and Wang C:
The risks associated with the use of lamotrigine during pregnancy.
Int J Psychiatry Clin Pract. 22:2–5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Diav-Citrin O, Shechtman S, Zvi N,
Finkel-Pekarsky V and Ornoy A: Is it safe to use lamotrigine during
pregnancy? A prospective comparative observational study. Birth
Defects Res. 109:1196–1203. 2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Yasam VR, Jakki SL, Senthil V,
Eswaramoorthy M, Shanmuganathan S, Arjunan K and Nanjan MJ: A
pharmacological overview of lamotrigine for the treatment of
epilepsy. Expert Rev Clin Pharmacol. 9:1533–1546. 2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Cohen-Israel M, Berger I, Martonovich EY,
Klinger G, Stahl B and Linder N: Short- and long-term complications
of in utero exposure to lamotrigine. Br J Clin Pharmacol.
84:189–194. 2018.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Dolk H, Wang H, Loane M, Morris J, Garne
E, Addor MC, Arriola L, Bakker M, Barisic I, Doray B, et al:
Lamotrigine use in pregnancy and risk of orofacial cleft and other
congenital anomalies. Neurology. 86:1716–1725. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pariente G, Leibson T, Shulman T,
Adams-Webber T, Barzilay E and Nulman I: Pregnancy outcomes
following in utero exposure to lamotrigine: A systematic review and
meta-analysis. CNS Drugs. 31:439–450. 2017.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Tomson T, Battino D, Bonizzoni E, Craig J,
Lindhout D, Sabers A, Perucca E and Vajda F: EURAP study group.
Dose-dependent risk of malformations with antiepileptic drugs: An
analysis of data from the EURAP epilepsy and pregnancy registry.
Lancet Neurol. 10:609–617. 2011.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Tomson T, Landmark CJ and Battino D:
Antiepileptic drug treatment in pregnancy: Changes in drug
disposition and their clinical implications. Epilepsia. 54:405–414.
2013.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Ding Y, Tan X, Zhang S and Guo Y:
Pharmacokinetic changes and therapeutic drug monitoring of
lamotrigine during pregnancy. Brain Behav. 9(e01315)2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Tran TA, Leppik IE, Blesi K, Sathanandan
ST and Remmel R: Lamotrigine clearance during pregnancy. Neurology.
59:251–255. 2002.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Baker GA, Bromley RL, Briggs M, Cheyne CP,
Cohen MJ, García-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G,
et al: Liverpool and Manchester Neurodevelopment Group: IQ at 6
years after in utero exposure to antiepileptic drugs: A controlled
cohort study. Neurology. 84:382–390. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Frey B, Schubiger G and Musy JP: Transient
cholestatic hepatitis in a neonate associated with carbamazepine
exposure during pregnancy and breast-feeding. Eur J Pediatr.
150:136–138. 1990.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Ladea M and Prelipceanu D: Markers of
vulnerability in schizophrenia. J Med Life. 2:155–164.
2009.PubMed/NCBI
|
|
75
|
De Santis M, De Luca C, Mappa I, Cesari E,
Quattrocchi T, Spagnuolo T, Visconti D and Caruso A: Antiepileptic
drugs during pregnancy: Pharmacokinetics and transplacental
transfer. Curr Pharm Biotechnol. 12:781–788. 2011.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Chen CY, Li X, Ma LY, Wu PH, Zhou Y, Feng
Q and Cui YM: In utero oxcarbazepine exposure and neonatal
abstinence syndrome: Case report and brief review of the
literature. Pharmacotherapy. 37:e71–e75. 2017.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Mines D, Tennis P, Curkendall SM, Li DK,
Peterson C, Andrews EB, Calingaert B, Chen H, Deshpande G, Esposito
DB, et al: Topiramate use in pregnancy and the birth prevalence of
oral clefts. Pharmacoepidemiol Drug Saf. 23:1017–1025.
2014.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Castilla-Puentes R, Ford L, Manera L,
Kwarta RF Jr, Ascher S and Li Q: Topiramate monotherapy use in
women with and without epilepsy: Pregnancy and neonatal outcomes.
Epilepsy Res. 108:717–724. 2014.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Veiby G, Daltveit AK, Engelsen BA and
Gilhus NE: Fetal growth restriction and birth defects with newer
and older antiepileptic drugs during pregnancy. J Neurol.
261:579–588. 2014.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Fujii H, Goel A, Bernard N, Pistelli A,
Yates LM, Stephens S, Han JY, Matsui D, Etwell F, Einarson TR, et
al: Pregnancy outcomes following gabapentin use: Results of a
prospective comparative cohort study. Neurology. 80:1565–1570.
2013.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Damkier P and Videbech P: The safety of
second-generation antipsychotics during pregnancy: A clinically
focused review. CNS Drugs. 32:351–366. 2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Bellantuono C, Di Massimo G, Mauro A,
Martellini M and Nardi B: Aripiprazole in pregnancy: A review of
literature. Riv Psichiatr. 50:8–11. 2015.PubMed/NCBI View Article : Google Scholar : (In Italian).
|
|
83
|
Galbally M, Frayne J, Watson SJ and
Snellen M: Aripiprazole and pregnancy: A retrospective, multicentre
study. J Affect Disord. 238:593–596. 2018.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Ballester-Gracia I, Pérez-Almarcha M,
Galvez-Llompart A and Hernandez-Viadel M: Use of long acting
injectable aripiprazole before and through pregnancy in bipolar
disorder: A case report. BMC Pharmacol Toxicol.
20(52)2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Pinheiro EA, Wisner KL and Clark CT:
Quetiapine dose adjustments in pregnant and postpartum women with
bipolar disorder. J Clin Psychopharmacol. 38:89–91. 2018.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Cohen LS, Góez-Mogollón L, Sosinsky AZ,
Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S and Freeman
MP: Risk of major malformations in infants following
first-trimester exposure to quetiapine. Am J Psychiatry.
175:1225–1231. 2018.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Spinelli MG: Accurate assessment of risk
of major malformations in infants with first-trimester exposure to
quetiapine. Am J Psychiatry. 175:1161–1162. 2018.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Brunner E, Falk DM, Jones M, Dey DK and
Shatapathy CC: Olanzapine in pregnancy and breastfeeding: A review
of data from global safety surveillance. BMC Pharmacol Toxicol.
14(38)2013.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Park Y, Hernandez-Diaz S, Bateman BT,
Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H and
Huybrechts KF: Continuation of atypical antipsychotic medication
during early pregnancy and the risk of gestational diabetes. Am J
Psychiatry. 175:564–574. 2018.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Pierre D, Péricaud A, Guerby P, Castel A,
Schmitt L and Yrondi A: Bitemporal electroconvulsive therapy during
the second trimester of pregnancy in bipolar disorders: A case
report. J ECT. 36:e14–e15. 2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Ward HB, Fromson JA, Cooper JJ, De
Oliveira G and Almeida M: Recommendations for the use of ECT in
pregnancy: Literature review and proposed clinical protocol. Arch
Women Ment Health. 21:715–722. 2018.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Coshal S, Jones K, Coverdale J and
Livingston R: An overview of reviews on the safety of
electroconvulsive therapy administered during pregnancy. J
Psychiatr Pract. 25:2–6. 2019.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Calaway K, Coshal S, Jones K, Coverdale J
and Livingston R: A systematic review of the safety of
electroconvulsive therapy use during the first timester of
pregnancy. J ECT. 32:230–235. 2016.PubMed/NCBI View Article : Google Scholar
|
